Skye Bioscience (SKYE) announced the debut of its “Anatomy of Progress” nimacimab development update video series and availability of presentations related to the development of its anti-obesity drug, nimacimab, presented in multiple forums at the American Diabetes Association’s 85th Scientific Sessions held June 20-23, 2025, in Chicago, Illinois. In this four-part video series, Skye discusses unmet needs in the obesity therapeutic space, advantages and benefits of its peripheral CB1-receptor-targeting antibody, which is designed to support healthy weight loss, and development progress of this novel CB1-inhibiting molecule.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.